After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo (Reuters) - GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's ...

SANOFI'S NEW BASAL INSULIN LANTUS XR, KNOWN AS TOUJEO IN THE U.S. AND EUROPE, APPROVED IN JAPAN FOR THE TREATMENT OF DIABETES MELLITUS Paris, France - July 3, 2015 - Sanofi announced today that the ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

Oct 19 (Reuters) - GoodRx (GDRX.O), opens new tab said on Thursday it has collaborated with Sanofi (SASY.PA), opens new tab to offer the drugmaker's most-prescribed insulin injection Lantus for only ...